Cardiovascular Toxicities Associated with Cancer Immunotherapies

被引：131

作者：

Wang, Daniel Y. ^{[1
]}

Okoye, Gosife Donald ^{[2
,3
]}

Neilan, Thomas G. ^{[4
,5
]}

Johnson, Douglas B. ^{[1
]}

Moslehi, Javid J. ^{[1
,2
,3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Oncol, 2220 Pierce Ave,777 Preston Res Bldg, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Med Ctr, Dept Med, Cardiovasc Med, Nashville, TN USA

[3] Vanderbilt Univ, Med Ctr, Dept Med, Cardiooncol Program, Nashville, TN USA

[4] Massachusetts Gen Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02114 USA

[5] Massachusetts Gen Hosp, Dept Med, Cardiooncol Program, Boston, MA 02114 USA

来源：

CURRENT CARDIOLOGY REPORTS | 2017年 / 19卷 / 03期

关键词：

Immune therapy; Checkpoint inhibitors; PD-1; CTLA-4; Cardiovascular toxicities; Myocarditis; CARDIAC TROPONIN-I; T-CELLS; RECOMBINANT INTERLEUKIN-2; DILATED CARDIOMYOPATHY; AUTOIMMUNE MYOCARDITIS; METASTATIC MELANOMA; HEART-FAILURE; PD-1; IPILIMUMAB; NIVOLUMAB;

D O I：

10.1007/s11886-017-0835-0

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Purpose of review We review the cardiovascular toxicities associated with cancer immune therapies and discuss the cardiac manifestations, potential mechanisms, and management strategies. Recent findings The recent advances in cancer immune therapy with immune checkpoint inhibitors and adoptive cell transfer have improved clinical outcomes in numerous cancers. The rising use of cancer immune therapy will lead to a higher incidence in immune-related adverse events. Recent studies have highlighted several reports of severe cases of acute cardiotoxic events with immune therapy including fulminant myocarditis. We believe that immune-mediated myocarditis is a driving mechanism behind these cardiovascular toxicities and requires vigilant screening and prompt management with corticosteroids and immune-modulating drugs, especially with combination immune therapies. Summary While the incidence of serious cardiovascular toxicities with immune therapy appears low, these can be life-threatening especially when manifesting as acute immune-mediated myocarditis. Further collaborative studies are needed to effectively identify, characterize, and manage these events.

引用

页数：11

共 68 条

[1]

Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3

[2]

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[3]

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[4]

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[5]

A two-step, two-signal model for the primary activation of precursor helper T cells [J].

Bretscher, PA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) :185-190

[6]

Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells [J].

Cameron, Brian J. ;

Gerry, Andrew B. ;

Dukes, Joseph ;

Harper, Jane V. ;

Kannan, Vivekanandan ;

Bianchi, Frayne C. ;

Grand, Francis ;

Brewer, Joanna E. ;

Gupta, Minnal ;

Plesa, Gabriela ;

Bossi, Giovanna ;

Vuidepot, Annelise ;

Powlesland, Alex S. ;

Legg, Alison ;

Adams, Katherine J. ;

Bennett, Alan D. ;

Pumphrey, Nicholas J. ;

Williams, Daniel D. ;

Binder-Scholl, Gwendolyn ;

Kulikovskaya, Irina ;

Levine, Bruce L. ;

Riley, James L. ;

Varela-Rohena, Angel ;

Stadtmauer, Edward A. ;

Rapoport, Aaron P. ;

Linette, Gerald P. ;

June, Carl H. ;

Hassan, Namir J. ;

Kalos, Michael ;

Jakobsen, Bent K. .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (197)

[7]

COLEY WB, 1991, CLIN ORTHOP RELAT R, P3

[8]

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors [J].

Curran, Michael A. ;

Montalvo, Welby ;

Yagita, Hideo ;

Allison, James P. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (09) :4275-4280

[9]

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia [J].

Davila, Marco L. ;

Riviere, Isabelle ;

Wang, Xiuyan ;

Bartido, Shirley ;

Park, Jae ;

Curran, Kevin ;

Chung, Stephen S. ;

Stefanski, Jolanta ;

Borquez-Ojeda, Oriana ;

Olszewska, Malgorzata ;

Qu, Jinrong ;

Wasielewska, Teresa ;

He, Qing ;

Fink, Mitsu ;

Shinglot, Himaly ;

Youssif, Maher ;

Satter, Mark ;

Wang, Yongzeng ;

Hosey, James ;

Quintanilla, Hilda ;

Halton, Elizabeth ;

Bernal, Yvette ;

Bouhassira, Diana C. G. ;

Arcila, Maria E. ;

Gonen, Mithat ;

Roboz, Gail J. ;

Maslak, Peter ;

Douer, Dan ;

Frattini, Mark G. ;

Giralt, Sergio ;

Sadelain, Michel ;

Brentjens, Renier .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)

[10]

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy [J].

Eggermont, A. M. M. ;

Chiarion-Sileni, V. ;

Grob, J. -J. ;

Dummer, R. ;

Wolchok, J. D. ;

Schmidt, H. ;

Hamid, O. ;

Robert, C. ;

Ascierto, P. A. ;

Richards, J. M. ;

Lebbe, C. ;

Ferraresi, V. ;

Smylie, M. ;

Weber, J. S. ;

Maio, M. ;

Bastholt, L. ;

Mortier, L. ;

Thomas, L. ;

Tahir, S. ;

Hauschild, A. ;

Hassel, J. C. ;

Hodi, F. S. ;

Taitt, C. ;

de Pril, V. ;

de Schaetzen, G. ;

Suciu, S. ;

Testori, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1845-1855

← 1 2 3 4 5 6 7 →